In this latest episode of ASTCT Talks, Dr. Andrés Gómez De León sits down with Dr. Javier Bolaños-Meade. They delve into the groundbreaking BMT CTN 1703 study.
Together, they explore the historical context of GVHD prophylaxis, the evolution of post-transplant cyclophosphamide (PTCy), and the essential contributions of the BMT CTN in transplantation research. Dr. Bolaños-Meade provides key insights into the study's design, conditioning regimens, and cell doses. The episode unravels the intricacies of PTCy, addressing both its merits and potential drawbacks, including Grade 2 infections, CMV reactivation, and cardiotoxicity, offering an exploration of the transformative impact of the BMT CTN 1703 study on the future of transplant medicine.
About Dr. Javier Bolaños Meade
Dr. Javier Bolaños Meade (@GvHD_Meade) is a Professor of Oncology at Johns Hopkins University School of Medicine, and clinical director of the BMT Programme at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, in Baltimore, Maryland. His research interest includes graft versus host disease prevention and therapy, as well as other complications of cell therapy.
About Dr. Andrés Gómez De León
Dr. Andrés Gómez De León (@GomezDLeonMD) is an Associate Professor at Universidad Autonoma de Nuevo Leon in Monterrey Mexico and an ASTCT Content Committee member with an interest in acute leukemias and transplant and cell therapies in low and middle income countries.
Tags: study, GVHD, BMT, PTCy, CMV